12.72
-0.04 (-0.31%)
| Previous Close | 12.76 |
| Open | 12.69 |
| Volume | 2,251,338 |
| Avg. Volume (3M) | 2,131,248 |
| Market Cap | 1,672,107,648 |
| Price / Earnings (TTM) | 84.80 |
| Price / Earnings (Forward) | 49.02 |
| Price / Sales | 6.49 |
| Price / Book | 2.46 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 7.85% |
| Operating Margin (TTM) | 15.24% |
| Diluted EPS (TTM) | 0.150 |
| Quarterly Revenue Growth (YOY) | 16.00% |
| Quarterly Earnings Growth (YOY) | 23.10% |
| Total Debt/Equity (MRQ) | 37.36% |
| Current Ratio (MRQ) | 13.23 |
| Operating Cash Flow (TTM) | 27.27 M |
| Levered Free Cash Flow (TTM) | 12.50 M |
| Return on Assets (TTM) | -0.38% |
| Return on Equity (TTM) | 3.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Dynavax Technologies Corporatio | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 0.34% |
| % Held by Institutions | 104.71% |
| 52 Weeks Range | ||
| Median | 29.00 (127.99%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Nov 2024 | 29.00 (127.99%) | Buy | 13.01 |
| 15 Oct 2024 | 29.00 (127.99%) | Buy | 10.76 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Nov 2024 | Announcement | Dynavax to Present at the 7th Annual Evercore HealthCONx Conference |
| 11 Nov 2024 | Announcement | Dynavax Announces $100 Million Accelerated Share Repurchase Program |
| 07 Nov 2024 | Announcement | Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 07 Nov 2024 | Announcement | Dynavax Announces $200 Million Share Repurchase Program |
| 29 Oct 2024 | Announcement | Dynavax Adopts Limited-Duration Stockholder Rights Plan |
| 24 Oct 2024 | Announcement | Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |